Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Leukemia & Lymphoma |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.3109/10428194.2011.652106 |
| Field | Oncology and hematology |
| Keywords | lenalidomide; dexamethasone; multiple myeloma |
| Attached files | |
| Description | The introduction of novel drugs (thalidomide, lenalidomide [immunomodulatory drugs; IMiDs] and bortezomib) optimistically changed the outcome of patients with multiple myeloma (MM) in terms of progressionfree and overall survival when compared to conventional chemotherapies. |
| Related projects: |
|